Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization.
Valsartan orodispersible tablets have been developed at 40-mg dose, with the intention of facilitating administration to patients experiencing problems with swallowing and hopefully, improving its poor oral bioavailability. Work started with selecting drug compatible excipients depending on differential scanning calorimetric analysis. A 3(3) full factorial design was adopted for the optimization of the tablets prepared by freeze-drying technique. The effects of the filler type, the binder type, and the binder concentration were studied. The different tablet formulas were characterized for their physical properties, weight variation, disintegration time, surface properties, wetting properties, and in vitro dissolution. Amongst the prepared 27 tablet formulas, formula number 6 (consisting of 4:6 valsartan:mannitol and 2% pectin) was selected to be tested in vivo. Oral bioavailability of two 40 mg valsartan orodispersible tablets was compared to the conventional commercial tablets after administration of a single dose to four healthy volunteers. Valsartan was monitored in plasma by high-performance liquid chromatography. The apparent rate of absorption of valsartan from the prepared tablets (C (max) = 2.879 microg/ml, t (max) = 1.08 h) was significantly higher than that of the conventional tablets (C (max) = 1.471 microg/ml, t (max) = 2.17 h), P < or = 0.05. The relative bioavailability calculated as the ratio of mean total area under the plasma concentration-time curve for the orodispersible tablets relative to the conventional ones was 135%. The results of the in vivo study revealed that valsartan orodispersible tablets would be advantageous with regards to improved patient compliance, rapid onset of action, and increase in bioavailability.
Ibrahim
Howida Kamal
HK
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El Aini Street, Cairo 11562, Egypt. Howidakamal@gmail.com
El-Setouhy
Doaa A
DA
D000328:Adult; D001682:Biological Availability; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004304:Dosage Forms; D005079:Excipients / Q000737:chemistry*; D005612:Freeze Drying; D006801:Humans; D008297:Male; D008875:Middle Aged; D013607:Tablets; D013777:Tetrazoles; D014633:Valine / Q000031:analogs & derivatives; D000068756:Valsartan
D004304:Dosage Forms; D005079:Excipients; D013607:Tablets; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine